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A B S T R A C T
Purpose: To examine the policies state governments pursued and enacted across the United States
in the 5-year period after the U.S. Food and Drug Administration licensed the human papilloma-
virus (HPV) vaccine in 2006, including the timing and number of bills introduced, the policies
proposed, and the legislative success of HPV vaccine policy proposals.
Methods: Content abstraction and analysis of state-level HPV vaccineerelated bills across the 50
states and the District of Columbia introduced between 2006 and 2010.
Results: All but five states (Alaska, Delaware, Idaho, New Hampshire, and Wyoming) introduced
HPV vaccine bills between 2006 and 2010. Two-thirds of all bills were introduced in 2007. In all,
141 bills were introduced and 23% or 32 bills were enacted. Of the bills that were enacted, 43.8%
provided information for parents and schools about the vaccine; 37.5% provided public financing
for HPV vaccines; 34.4% were classified as other policies; 25% created awareness campaigns; 25%
required private insurance coverage of the HPV vaccination; 12.5% included voluntary vaccination,
and 9.4% mandated vaccination for school entry. One bill reversed prior mandatory vaccination
policies. Overall, 91% of enacted HPV vaccine bills did not refer to mandated vaccinations but
adopted alternate policy strategies in response to the availability of the new HPV vaccine.
Conclusions: Nationwide, states responded to the new HPV vaccine by introducing policies
designed to increase the availability of information about the vaccine, provide funding, and
regulate private insurance coverage rather than require vaccination for school entry.
 2014 Society for Adolescent Health and Medicine. All rights reserved.
IMPLICATIONS AND
CONTRIBUTION
After the human papillo-
mavirus (HPV) vaccine
was licensed, many states
introduced bills requiring
vaccination for school en-
try. We measure the suc-
cess of these bills and
show that while school
entry policies were mostly
unsuccessful, legislatures
enacted many other pol-
icies to encourage uptake
of the HPV vaccine.
The development of the prophylactic human papillomavirus
(HPV) vaccine was hailed as a scientific and public health
breakthrough in the prevention of cervical cancer [1]. The U.S.
Food and Drug Administration (FDA) approved the quadrivalent
vaccine (Gardasil) in 2006 [2,3]. Gardasil prevents infection from
HPV because of variants 16 and 18 [4,5], which account for 70% of
all cervical cancers, and variants 6 and 11 that can lead to genital
warts [6]. The Centers for Disease Control and Prevention Advi-
sory Committee on Immunization Practices (ACIP) added the
quadrivalent (HPV4) vaccine to the immunization schedule for
girls aged 11e12 years in 2006 [7] and recommended funding the
vaccine under the Vaccine for Children Program in 2006. In 2009,
the FDA approved the bivalent vaccine that protects against
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variants 16 and 18 (Cervarix), and that year, Gardasil was licensed
for use in males for prevention of genital warts [8]. The FDA
extended the application of the vaccine to anal cancer in males
and females in December 2010 [8]. In December 2011, the ACIP
recommended routine vaccination of males aged 11e12 years
with Gardasil administered as a 3-dose series [8].
Early on, enacting HPV vaccine policies was seen as poten-
tially politically challenging [9e12]: given that the vaccine pre-
vented sexually transmitted diseases and was initially approved
for young girls starting in middle school. Immediately after its
approval, however, elected officials in state legislatures eagerly
introduced legislation to encourage the uptake of the vaccine in
their states and many state legislators seemed supportive of HPV
vaccine policies [13]. As more states proposed mandating vacci-
nation as a requirement of school entry, however, earlier pre-
dictions that the vaccine would be a politically contentious issue
suddenly appeared prescient and controversy grew [14e16],
especially around mandatory vaccination policies [11,17,18].
Research has explored the ethical, legal, and political debates
surrounding the introduction of the HPV vaccine [9,19] including
case studies of specific states [20]. Most studies have focused on
mandatory vaccination policy [12,21,22]. Less is known about the
range of policy approaches contemplated and adopted by states
and the success of policies other than mandatory vaccination. To
understand early policy responses to the introduction of the
HPV vaccine, we compiled a unique data set of 141 HPV vaccine-
related bills introduced in the United States between 2006 and
2010. We coded policies mentioned in these bills by topic and
tracked which bills were enacted in order to characterize na-
tional trends in the success and failure of state-level HPV vaccine
bills.
Our detailed analysis of bill content in 50 states and the
District of Columbia reveals the full range of policy strategies
pursued after the HPV vaccine was introduced. HPV vaccine bills
incorporating policies other than mandated vaccination were
passed at similar rates (and sometimes at higher rates) than
other bills; furthermore, states introducing and passing legisla-
tion included a mix of traditionally “red” and “blue” states. Our
large sample, along with a detailed analysis of state bills, offers a
more complete understanding of the policy options states can
potentially explore; it also indicates that there is some support
for HPV vaccine legislationwhen bills include policies other than
mandated vaccination.
Methods
The National Conference of State Legislatures’ (NCSL) regu-
larly updated list, “HPV Vaccine: Introduced Legislation” [23],
was used to find HPV vaccine bills. The NCSL identified bills using
databases State Net, LexisNexis, and Westlaw. We also searched
state legislative Web sites using terms “HPV,” “human papillo-
mavirus,” (with the Boolean operator AND) “vaccine.” Bills
introduced in the 50 states and the District of Columbia between
January 1, 2006 and December 31, 2010 were included. The NCSL
included an executive order, which was included in our sample.
Bills were defined as legislative proposals, which included
resolutions passed in state legislatures. Resolutionswere included
in the sample to make the study comparable with other studies of
legislative rates of enactment, but as discussed in the following,
resolutions are different fromother bills. To be eligible, bills had to
refer to the HPV vaccine or vaccination, or immunization. Nine
bills were excluded on this basis, because they referred to HPV but
not the HPV vaccine or immunization against HPV.
To check the accuracy of our sample, we also checked state
and District of Columbia codes using LexisNexis and the National
Cancer Institute’s State Cancer Legislative Database (SCLD) of
laws [24]. We found that three bills were not included on the
NCSL list, but only onewas eligible for inclusion. The status of one
bill in the sample was revised from “not enacted” to “enacted.”
The final sample included 141 unique legislative bills (including
one executive order).
Two coders used content analysis methods [25] and worked
independently. The initial coding schema included categories of
financing, information, and mandatory vaccination. These defi-
nitions drew on the SCLD database of cancer-related laws [24].
These categories were refined and a more detailed schema was
used that included a fourth category of “backlash bills” for
opposing mandatory vaccination.
Finance bills were coded as either expanding access to vac-
cinations using public funding and/or mandating private insur-
ance coverage of the vaccine. Information bills included those
designing, creating, producing, and/or disseminating informa-
tional materials on the HPV vaccine (e.g., fact sheets, usually for
distribution to schools, parents, and school-aged females).
Awareness bills included bills that proposed broader dissemi-
nation of information on the HPV vaccine to the public, such as
the development of public awareness campaigns and Web sites.
The SCLD database [24] of state laws distinguishes among
vaccination requirement laws. The term “mandates” or
“mandatory” vaccination is used in most discussions of vacci-
nation requirements [10,12,16,17,21,22,26]. Bills requiring HPV
vaccinations for school entry were coded as mandatory vacci-
nation if the law mentioned “required” or “mandated” vaccina-
tion. If the bill explicitly stated the HPV vaccinewas “not required
for school entry,” we coded the bill as “voluntary vaccination.”
However, it should be noted that states also have existing laws
that provide exemptions from vaccination requirements.
Bills included in the “other policies” code were sufficiently
distinct from existing categories but not numerous enough to
warrant a separate category; for example, seven bills proposed
tracking of immunization rates, three bills proposed adding HPV
to a teen vaccine program, and one bill would give the state
Health and Human Services Commissioner the power to modify
or delete immunizations. Determining the number of coding
categories and a minimum frequency count requires considering
the advantages of adding a separate code; one guideline is a
maximum of seven categories [27]. If the topic was both infre-
quent and sufficiently distinct from existing categories, it was
coded as other. Second, all bills that were resolutions were coded
as other. Resolutions are often expressions of sentiment, intent,
or positions on issues, and do not have the force of law [24e28].
Eleven bills mentioning studies of the HPV vaccine and cer-
vical cancer and designations of certain months as HPV vacci-
nation awareness months were legislative resolutions and coded
as other. Four bills adding HPV vaccine information to the school
sex education curriculum were coded as other, because they
focused on changes to school curriculums rather than distribu-
tion of informational materials. One bill relating to funding of
educational materials was coded as other, because although the
bill referred to education materials, the category of funding
specifically referred to vaccine provision or mandating insurance
coverage. Two bills encouraging schools to give parents HPV
information were not included in the information category
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because they did not require the design, creation, production,
and/or dissemination of information materials.
The date the bill was introduced and passed (if applicable) was
recorded, although the time to legislation is not necessarily
comparable across states, however, given variation in state legis-
lative terms. Each bill was coded according towhether it became a
law or failed. Legislative histories or statements on the progress of
a bill available on state legislativeWeb sites were used to code the
status of the bill and also checked in the SCLD (as mentioned
previously) [24]. Bills were considered enacted based on NSCL
criteria: if they were enrolled, ratified, passed by the legislature
and signed into law by the Governor; or if the legislature had a
sufficientmajority tomake gubernatorial assent unnecessary [28].
Bills that died in committee were withdrawn by the bill’s author,
or postponed indefinitely, vetoed, never progressed, or enacted
but were repealed in the same session were coded as failed.
We explored the possibility of tracking the stage in the leg-
islative process at which bills failed. However, many state legis-
latures have rules that essentially force bills to go through
particular steps; thus bills would seem to proceed further than
theywouldwithout those rules. For example, 22 statesmust hold
hearings on all bills, 18 must report all bills referred, and others
have processes for formally “killing” bills while others do not.
Each of these powers can vary by chamber [29].
Ninety-five percent of the sample was tested for reliability
using the program ReCal [30]. Not all bills in the sample (5%)
were tested because we subsequently added legislative resolu-
tions in the sample to make the selection comparable with
studies of legislative enactment rates and because the checks
described earlier required adding a bill to the sample. Krippen-
dorff alpha was .87 for vaccine policies (a variable which coded
school entry requirements as mandatory or voluntary) and .93
for HPV vaccine information and awareness campaigns. Public
funding and mandated insurance benefits scored 1.0 in both
categories. All discrepancies between the two raters were
resolved and corrected by the lead author.
Results
Between January 2006 and December 2010, 141 bills
(including one executive order) related to HPV vaccination were
introduced in 45 states and the District of Columbia. Two-thirds
(94 bills) of all HPV vaccineerelated bills were introduced in
2007 (Figure 1). Examples of bills by topic are shown (Table 1).
On average, most bills proposed 1.7 policies per bill. Bills could
havemultiple policies, so the number of bill topics is greater than
the number of bills.
New York proposed the most bills (13 bills), followed by Texas
(9), New Jersey (8), Michigan (7), Iowa, and Pennsylvania (6
each). Most states approved at least one bill, although Colorado,
New Jersey, and Texas adopted 25% of the 32 HPV vaccine laws.
The most populous state, California, did not enact any HPV vac-
cine legislation. Five states (not shown) did not introduce any
HPV vaccine legislation during the time studied: Alaska, Dela-
ware, Idaho, New Hampshire, and Wyoming.
Twenty-six states and the District of Columbia enacted
32 bills. On average, enacted bills took 96 days to become
law. The overall rate of enactment for HPV vaccine bills intro-
duced was 23%.
A total of 241 policy interventions were identified (Table 2),
including requiring vaccination for school entry, creating public
awareness programs, providing direct programmatic funding of
vaccine provision. States also proposed regulating private in-
surance coverage for HPV vaccination, and some states sought to
reverse earlier policies relating to mandatory vaccination.
Forty-one percent of introduced bills referred to the produc-
tion and dissemination of information on the HPV vaccine; 28.4%
required private insurance coverage for HPV vaccination; 27%
proposed public funding for HPV vaccination; 27.7% referred to
mandatory vaccination; 22.7% were classified as “other” policies;
12.1% referred to awareness campaigns, and 8.5% of the bills
introduced referred to voluntary vaccination. Five bills proposed
removing prior mandated vaccination policies.
Among enacted bills, creation and dissemination of infor-
mation about the vaccine to parents and schools was mentioned
in 43.8% of bills and 37.5% of enacted bills provided public
funding for vaccines. A little over one-third (34.4%) of bills
mentioned other policies, 25% of bills required private insurance
coverage of the vaccine, and 25% of bills referred to general
awareness campaigns. Voluntary vaccination requirements
(12.5%) and mandatory vaccination requirements (9.4%) and a
single backlash law accounted for the smallest category of
enacted bills.
Table 3 displays state-by-state variations in the bills intro-
duced and enacted, by topic. States across the United States
introduced legislation, including states from the northeast,
southeast, south, midwest, and western states. Mandatory
vaccination bills were successfully enacted by Texas, Virginia,
and Washington DC.
Discussion
The aim of the study was to understand the nature of early
HPV vaccineerelated policy proposals and assess which policies
were successfully enacted. Drawing on a unique 50-state (and
Washington DC) data set, we compiled and coded bills drawn
from primary legislative sources. We reviewHPV vaccine policies
proposed throughout the United States and describe the early
state-level policy responses to the licensing of HPV vaccines in
the first 5 years after it was available.
Researchers have explored states’ responses to the new HPV
vaccine, but typically this has been analyzed in specific states or
Figure 1. Human papillomavirus vaccine bills introduced and enacted in the
United States between 2006 and 2010.
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subsets of states [20,31]. Studies have also explored the ethical,
legal, and political aspects of the HPV vaccine and the nature of
the public debate around the vaccine [10e12,16,17,19,21].
Generally, discussion of the policy response to the new vaccine
has focused on legislative proposals to mandate vaccination. This
is somewhat understandable, given the effectiveness of vaccine
requirements in encouraging vaccination of children: this
approach has worked well for many communicable diseases.
However, there are two advantages to considering the
nationwide response beyond mandated vaccination policies.
First, a national sample allows us to understand how often and
where HPV legislation was introduced and passed. There was a
concern that the HPV vaccine would not be well received in
states with more conservative views regarding premarital sex
and sexuality [9e12]. Yet HPV legislation was passed at rates
comparable to state legislation overall: the enactment rate for
HPV legislation is only slightly less than the 2007 rate of enact-
ment for all bills: 27.5% of state bills introduced were successful
[32]. Obesity prevention legislation success rates range between
17% and 27% [33,34]. In addition, legislation has also been
introduced in states where Republican presidential candidates
tend to prevaild“red” states [35], such as Kentucky, Mississippi,
Texas, Utah, and Virginia. Some traditionally blue states, such as
California, failed to enact HPV vaccine legislation or only passed
one bill (New York).
A second advantage of this approach is that capturing the
legislative response across all states allows inclusion of states
that did not introduce mandatory vaccination bills and tracks
laws that states adopted with relative ease. Although mandatory
vaccination requirements werementioned in 39 bills or 27% of all
bills introduced in the United States, not all states introduce
these mandates and <10% of enacted bills included mandatory
vaccine requirements. In comparison, 44% of enacted bills
included informational requirements and 25% of bills enacted
required insurance coverage of the vaccine. Although these
policies alone are unlikely to substantially increase HPV vacci-
nation rates, policies such as these are a necessary component of
vaccination policy [36,37]. In the absence of a HPV vaccine
mandate, these policies may serve to complement other
mandatory vaccination requirements, indeed states with tetanus
vaccination requirements have higher rates of HPV vaccination
[26].
Our study has limitations, including the potential for subjec-
tivity, which is one risk of content analysis methods. To address
this problem, two coders assessed the bills. Intercoder reliability
analysis was assessed for 95% of the bills, rather than a sample of
bills. Discrepant codes were resolved using consensus between
the two coders and the lead author. As a study of new bills
specifically referring to HPV vaccines, we capture new policies
introduced in the legislative process but not existing laws already
Table 1
Types of human papillomavirus (HPV) policies and examples of bills introduced in the United States
Category Specific policies Example
Financing Public funding South Dakota, HB 1061 c 201: Public funding for HPV vaccine
programs. (2007, passed)
Private insurance coverage Nevada, S 1230 c. 527: Private insurers required to cover the
HPV vaccine. (2007, passed)
Vaccine information Educational materials and publications Illinois HB 2033: Department of Health to distribute
information about the HPV virus and vaccine. (2009, failed)
Awareness campaigns Iowa SB 326: Public awareness program for human
papillomavirus infection vaccination. (2007, failed)
Vaccination and/or school
entry requirements
Mandatory vaccination Virginia S 1230/Chapter 922: Females to receive the HPV
vaccination before the sixth grade for school attendance.
(2007, passed)
Voluntary vaccination New York A 3203/S 1983: Voluntary vaccination. (2010, failed)
“Backlash” policies Reversal of prior HPV vaccine policies Virginia, HB 686: Removal of the HPV vaccine from the list of
required vaccinations. (2010, failed)
Other HPV vaccine awareness months, study taskforces, adding to a
teen vaccine program or school curriculum, funding
educational materials, tracking vaccine rates, encouraging
schools to give parents information, and expanding executive
authority to modify or delete immunizations.
Maryland, Chapter No. 191, H.B. 1049: Taskforce for HPV
vaccine, 2007.
Table 2
Policies included in state human papillomavirus vaccine bills introduced and enacted 2006e2010
Policies included in billsa Introduced bills that included this
policy (n ¼ 141), n (%)
Enacted bills that included this
policy (n ¼ 32), n (%)
Percentage enacted
“Backlash” or reversals of mandated vaccination laws 5 (3.5) 1 (3.1) 20
General awareness campaigns 17 (12.1) 8 (25.0) 47.1
Mandated vaccination for school entry 39 (27.7) 3 (9.4) 7.7
Other policies 32 (22.7) 11 (34.4) 34.4
Private insurance coverage for vaccine 40 (28.4) 8 (25.0) 20.0
Production and dissemination of vaccine information 58 (41.1) 14 (43.8) 24.1
Public funding for vaccines 38 (27.0) 12 (37.5) 31.6
Voluntary vaccination for school entry 12 (8.5) 4 (12.5) 33.3
The sample includes 50 states and the District of Columbia.
a One hundred forty-one bills were introduced and 32 bills were enacted. The percentages do not add up to 100%, because the denominator is the number of bills
introduced or enacted: on average, bills included 1.7 policies per bill.
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encompassing the HPV vaccine but not specifically mentioning
the vaccine. This is common in studies that rely on searches using
keywords. [34] The data set does not allow us to highlight
particular subpopulations or address the role of health dispar-
ities or particular populations at risk such as lesbian, bisexual, or
transgender populations. Finally, although we present the fre-
quencies of introduced and adopted legislation, we do not con-
trol for state characteristics such as economic conditions or the
political composition of the legislature sometimes associated
with adoption of policies such as obesity prevention [38].
The study shows how states took this role on in the first 5
years after the vaccine was available; since that time, the scien-
tific understanding of the vaccine and the indications for its use
have steadily expanded. To assess subsequent developments
since 2010, we reviewed the NCSL [23] summary list of bills
introduced that refer to the HPV vaccine introduced after January
1, 2011 through February 2014. Since 2011, 31 bills were intro-
duced across all the topics in our codebook, with 16 bills intro-
duced in 2011e2012 and 15 bills introduced in 2013e2014.
Notably, six insurance coverage bills were introduced, despite
new federal requirements for coverage of the vaccine; five
mandatory vaccination bills were introduced. Georgia, Hawaii,
Indiana, Iowa, Kentucky, New Jersey Ohio, and South Carolina
each introduced bills. New York introduced the most bills (7)
followed by Virginia (5). Between 2011 and 2012, no bills were
passed. Two bills that passed between 2013 and 2014 included an
awareness month resolution (Pennsylvania) and a bill allowing
pharmacists to administer the vaccine (Indiana).
Table 3
States introducing and enacting human papillomavirus (HPV) vaccine policies 2006e2010











Alabama B B B
Arizona B B B B B
Arkansas B B
California B B B B
Colorado C C C C B C C
Connecticut B B B B B
District of Columbia C
Florida B B B
Georgia B B B B
Hawaii B B B C
Illinois C C B B C
Indiana C C
Iowa B B C B C
Kansas B B B
Kentucky B B B B B
Louisiana B C
Maine C C C C B
Maryland B C B C
Massachusetts B B
Michigan C B C
Minnesota C B B B C
Mississippi B B B B




New Jersey B B C C
New Mexico C C B B C
New York C B B B B B
North Dakota C




Pennsylvania C B C B C
Rhode Island C
South Carolina B B
Tennessee
South Dakota C C
Texas C C C C C C
Utah C C C
Vermont B B




C, Enacted policy;B, Introduced but not enacted policy.
Each circle represents at least one bill or enactment. Because the same topic can be introduced more than once, the number of dots does not equal the total number of
bills introduced.
Alaska, Delaware, Idaho, New Hampshire, and Wyoming did not introduce or pass any HPV vaccine legislation.
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States are likely to continue to be important venues for vac-
cine policymaking, although federal public funding for childhood
vaccines continues to be available through the Vaccines for
Children program, and the Patient Protection and the Affordable
Care Act now requires private insurers to cover ACIP-approved
vaccines at no cost to the patient. Political support for public
health laws at the state level may be stronger than support at the
federal level. The enactment rate (23%) for state HPV vaccine bills
is substantially higher than health bills in Congress, (1973e2002),
where just 4% of bills succeeded. Less than one percent of bills
relating to the prevention of communicable diseases succeeded
in Congress. Meanwhile, successful public health initiatives are
flourishing in cities such as New York City. [39] For the most part
vaccination efforts will remain in the hands of the state and local
public health authorities. Although HPV vaccination mandates
continue to be mostly unsuccessful, opportunities to enact vac-
cine legislation at the state level may still bemore successful than
legislation introduced at the federal level.
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